Is there a tirzepatide 25 mg dose — and what does that mean for your treatment?

Does tirzepatide come in a 25 mg strength?

No. In the UK, tirzepatide (sold under the brand name Mounjaro) is available in six pre-filled pen strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each pen delivers four once-weekly doses. Treatment opens at the lowest strength, which is there to let the body adjust, and moves upward in roughly four-week steps as directed by your prescriber. Fifteen milligrams is the ceiling; there is no 20 mg, no 25 mg, no higher option in the licensed schedule. This is set out in the Mounjaro Summary of Product Characteristics, which you can read via the eMC medicines database.

So where does the 25 mg figure come from? Almost always, it refers to oral semaglutide (Wegovy tablets) which the MHRA approved for weight management in June 2026 as the first oral GLP-1 medicine of its kind in the UK. Its maintenance dose is 25 mg daily. These are distinct molecules with different mechanisms, different titration ladders, and different licensed strengths. Searching 'tirzepatide 25 mg' is a common mismatch, and one that's easy to make when both medicines appear in weight-loss conversations side by side.

The practical upshot: if you were hoping to find a higher tirzepatide dose, 15 mg is genuinely the top of the range. If you read about 25 mg and it appealed, you may actually be thinking about the Wegovy tablet. A prescriber can talk through which route suits your circumstances.

What are the tirzepatide strengths, and how does the titration actually work?

A question our prescribers hear most weeks is whether the starting dose is too low to do anything useful. The honest answer is that the 2.5 mg starting dose is designed specifically to settle your system rather than to drive weight loss immediately. Starting low reduces the nausea and gastrointestinal discomfort that can accompany the first weeks on any GLP-1 or dual-agonist treatment. The body adapts, and the dose climbs.

The full schedule, as set by the prescriber and described in the licensed product information, moves through 2.5 mg, then the 5 mg dose, where many patients begin to notice the appetite-suppressing effects more clearly, 7.5 mg, 10 mg, 12.5 mg and finally 15 mg. Not every patient reaches 15 mg, the prescriber decides at each review whether to continue titrating or to stay at the highest tolerated dose. Clinical trial data published in the SURMOUNT-1 study in the New England Journal of Medicine reported average body-weight reductions of around 20–21% over 72 weeks at the 15 mg dose in participants without diabetes. Those figures are from a controlled trial; individual results vary and are assessed alongside clinical review at each stage.

If you want to read more about a specific point in the titration schedule, the tirzepatide dose overview covers each step in detail. The key point here is simply that 25 mg does not feature in that schedule at any point.

How does tirzepatide at 15 mg compare with the oral semaglutide 25 mg dose?

Both medicines target weight management in adults who meet licensing criteria, but they operate differently. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) making it the only dual agonist licensed for weight management in the UK. Oral semaglutide (Wegovy tablets) acts on the GLP-1 receptor only, though it delivers semaglutide in a tablet form using an absorption enhancer, which is a meaningful practical difference for people who prefer not to inject.

On results, the OASIS 4 phase-3 trial for the 25 mg oral semaglutide tablet reported an average weight reduction of around 13.6% over 64 weeks, rising to roughly 17% among participants who adhered fully throughout. SURMOUNT-1 reported around 20–21% at tirzepatide 15 mg over 72 weeks. Direct comparisons between studies are imperfect because trial designs, populations and durations differ; nonetheless, the NHS England weight management guidance and NICE TA1026 discussion notes acknowledge that indirect comparisons tend to favour tirzepatide on average weight reduction.

What the numbers can't settle is which medicine is right for a given person. Tolerability, medical history, other medicines, and preference for injection versus tablet all factor in. You can read about the broader treatment options we offer, and the consultation is where those factors get worked through properly. Pricing context for private treatment, if that is relevant to your decision, is covered on our treatment page.

What should you do if you were searching for a higher tirzepatide dose?

If you reached this page hoping to find a tirzepatide pen stronger than 15 mg, there are a couple of possibilities worth considering. First, the 15 mg dose in clinical trials produced results comparable to or greater than many medicines at any dose, so 'higher' does not necessarily mean 'more effective for you personally'. Second, if oral semaglutide's 25 mg tablet appeals because you prefer not to inject, that is a straightforward clinical conversation to have. It is also worth knowing that a 1 mg tirzepatide option exists for those who need a more gradual introduction than the standard 2.5 mg starting point, so there is genuine flexibility at the lower end of the range too.

What matters more than any single dose number is whether the medicine, the dose, and the clinical oversight are right for your situation. Sellers advertising tirzepatide strengths that don't appear in the licensed schedule (or offering these medicines without a full clinical assessment) are a red flag; the MHRA has warned publicly about counterfeit and illegally traded weight-loss pens, and legitimate supply is traceable through the GPhC pharmacy register.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day it's submitted. There are no algorithms making clinical calls. If you'd like to understand your options properly, you're welcome to speak to our prescribers through a free consultation, no obligation, no subscription.